5Y6 Stock Overview Operates as a mental health care company in the United Kingdom and the United States. More details
Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
COMPASS Pathways plc Competitors Price History & Performance
Summary of share price highs, lows and changes for COMPASS Pathways Historical stock prices Current Share Price US$4.12 52 Week High US$11.70 52 Week Low US$3.16 Beta 2.29 1 Month Change 14.44% 3 Month Change -10.43% 1 Year Change -56.86% 3 Year Change -66.91% 5 Year Change n/a Change since IPO -87.40%
Recent News & Updates
Compass Pathways plc Appoints Steve Levine, M.D., as Chief Patient Officer Jan 21
compass Pathways plc Announces the Termination of Matthew Allen Owens as A Director Jan 16 COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.767589 million. Jan 10
COMPASS Pathways plc Announces Business Updates Oct 31
COMPASS Pathways plc to Report Q3, 2024 Results on Oct 31, 2024 Oct 24
New major risk - Shareholder dilution Oct 09 See more updates
Compass Pathways plc Appoints Steve Levine, M.D., as Chief Patient Officer Jan 21
compass Pathways plc Announces the Termination of Matthew Allen Owens as A Director Jan 16 COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.767589 million. Jan 10
COMPASS Pathways plc Announces Business Updates Oct 31
COMPASS Pathways plc to Report Q3, 2024 Results on Oct 31, 2024 Oct 24
New major risk - Shareholder dilution Oct 09
COMPASS Pathways plc Appoints Gino Santini as Chairman Effective September 3, 2024 Aug 01
Compass Pathways plc Appoints Lori Englebert as Chief Commercial Officer, Effective July 8, 2024 Jun 26
Insider recently sold €114k worth of stock May 24
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder May 09
COMPASS Pathways plc, Annual General Meeting, May 09, 2024 Apr 09
New major risk - Shareholder dilution Mar 07
Co-Founder & Director recently sold €281k worth of stock Mar 03
COMPASS Pathways plc to Report Q4, 2023 Results on Feb 29, 2024 Mar 01
New major risk - Revenue and earnings growth Dec 12 COMPASS Pathways plc Announces Management Changes
COMPASS Pathways plc Announces Chief Financial Officer Changes Dec 07
COMPASS Pathways plc to Report Q3, 2023 Results on Nov 02, 2023 Nov 02
Compass Pathways plc Announces Executive Changes, Effective November 3 ,2023 Oct 27
Compass Pathways plc Announces the Appointment of Daphne Karydas to Its Board of Directors Sep 20 COMPASS Pathways plc announced that it expects to receive $125 million in funding from a group of investors Aug 17
New major risk - Financial position Jul 03
Compass Pathways Announces Resignation of Ekaterina Malievskaia as Chief Innovation Officer, Effective from June 16, 2023 Jun 01
Compass Pathways plc Announces Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of Comp360 Psilocybin Therapy to Be Presented At Asco 2023 May 27
COMPASS Pathways plc to Report Q1, 2023 Results on May 11, 2023 May 12
COMPASS Pathways plc Announces COMP360 Psilocybin Therapy Shows Potential in Open-Label Study in Type II Bipolar Disorder Presented At ACNP Dec 09
COMPASS Pathways plc Launches Phase II Clinical Trial of Psilocybin Therapy in Anorexia Nervosa Jul 29
COMPASS Pathways plc to Report Q2, 2022 Results on Aug 04, 2022 Jul 28
Compass Pathways Appoints Kabir Nath as Chief Executive Officer Jul 20
COMPASS Pathways plc Presents Largest Ever Study of Psilocybin Therapy, At American Psychiatric Association Annual Meeting May 24
Compass Pathways plc Announces Positive Data Demonstrating the Potential of COMP360 Psilocybin Therapy in Anorexia Nervosa and Severe Treatment-Resistant Depression Has Been Presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from Two Investigator-Initiated Studies May 05
COMPASS Pathways plc to Report Q1, 2022 Results on May 10, 2022 May 04
COMPASS Pathways plc, Annual General Meeting, Jun 16, 2022 Apr 23
COMPASS Pathways plc Announces Jason Camm Not to Stand for Re-Election as A Director Apr 22
COMPASS Pathways plc to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
COMPASS Pathways plc Study of 89 Healthy Participants Published in Journal of Psychopharmacology Jan 06
Compass Pathways Announces Positive Outcome of 25Mg Comp360 Psilocybin Therapy as Adjunct to Ssri Antidepressants in Open-Label Treatment-Resistant Depression Study Dec 14
Compass Pathways Announces Further Positive Results from Phase IIb Trial of Investigational Comp360 Psilocybin Therapy for Treatment-Resistant Depression Dec 02
COMPASS Pathways plc Pathways Granted Fifth US Patent for Crystalline Psilocybin Nov 24
Compass Pathways and Kings College London Publish Cognition Results from Comp360 Psilocybin Study in Healthy Volunteers Jun 04
Independent Director has left the company May 27
New 90-day low: €32.00 Mar 05 Shareholder Returns 5Y6 DE Biotechs DE Market 7D 3.0% 1.2% 2.3% 1Y -56.9% -5.6% 16.7%
See full shareholder returns
Return vs Market: 5Y6 underperformed the German Market which returned 15% over the past year.
Price Volatility Is 5Y6's price volatile compared to industry and market? 5Y6 volatility 5Y6 Average Weekly Movement 12.8% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 5Y6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5Y6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
Show more COMPASS Pathways plc Fundamentals Summary How do COMPASS Pathways's earnings and revenue compare to its market cap? 5Y6 fundamental statistics Market cap €295.34m Earnings (TTM ) -€139.21m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5Y6 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$144.32m Earnings -US$144.32m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 22:34 End of Day Share Price 2025/02/11 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources COMPASS Pathways plc is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Thomas Shrader BTIG Sumant Satchidanand Kulkarni Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Show 11 more analysts 